

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia

Batch 33

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation on the draft scope consultees noted that the options for some people with chronic myeloid leukaemia (CML) or acute lymphoblastic leukaemia (ALL) are limited if the only suitable treatment is allogeneic stem cell transplant. Older people, or people with significant co-morbidities may not be eligible for transplant, and there are difficulties in finding suitable donors for people from ethnic minorities

One consultee noted that access to ponatinib is currently inequitable across the UK, specifically that people with CML or ALL in England can only receive ponatinib if they have the T315I mutation, whereas in Scotland and Wales ponatinib is available for its full licensed indication for both chronic myeloid leukaemia and acute lymphoblastic leukaemia.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The current options for people with CML or ALL will be taken into account during the committee's discussions about the role of ponatinib in the current treatment pathway. NICE's appraisal committees' remit is for England only; the devolved administrations have their own processes for appraising technologies.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): ...Frances Sutcliffe.....

Date: 28/07/2016